Skip to content
Home/Companies/Biotech/Delinia

Delinia

Biotech·United Kingdom·Exited 2017·Held 1yr
Entry
2016
Hold
1yr
Exit
2017

Who owns Delinia?

Delinia is a British Biotech company, now owned by Celgene, which acquired it in 2017 from Sofinnova Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
Sofinnova Partners
Investor
Sofinnova Partners
Sofinnova Capital VIII · 2015 · Life Sciences VC

Key facts

HQUnited Kingdom
SectorBiotech
Exit Type
Trade Sale
Buyer
Celgene
Exit Year
2017

More from Sofinnova Capital VIII

Other portfolio companies in the same fund.

VectivBio
Exited 2023
BiotechSwitzerland· 2017
to Ironwood Pharmaceuticals
Breath Therapeutics
Exited 2019
BiotechGermany· 2016
to Zambon
Corvidia Therapeutics
Exited 2020
BiotechUS· 2016
to Novo Nordisk
ENYO Pharma
ENYO Pharma
Active
BiotechFrance· 2016
ReCor Medical
Exited 2018
MedTechUS· 2016
to Otsuka Holdings
BiovelocITA
Active
BiotechItaly· 2015

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Abbisko Healthcare
Active
The Carlyle GroupChina
Adagene
Active
General AtlanticChina
Advanced Cell Diagnostics
Active
Summit PartnersUS
Akero Therapeutics
Akero Therapeutics
Active
General AtlanticUS
Aldevron
Aldevron
Active
TA AssociatesUS
Alloy Therapeutics
Alloy Therapeutics
Active
Mubadala CapitalUS

Questions

Who owns Delinia?

Delinia is now owned by Celgene, which acquired it in 2017 from Sofinnova Partners.

When did Celgene acquire Delinia?

Celgene acquired Delinia in 2017, buying from Sofinnova Partners.

Who did Delinia sell to?

Sofinnova Partners sold Delinia to Celgene in 2017 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue